Sanofi’s Pompe disease drug shortage disrupts U.S. patient infusions

As reported on November 19, 2026, a supply disruption affecting Sanofi’s Pompe disease treatments had lasted more than three months, causing some patients to miss scheduled infusions. Sanofi said it had made progress restoring supplies in some countries, but shipping delays could interrupt infusions for some U.S. patients through the end of November.

Sanofi attributed the shortage to issues at its manufacturing facility in Ireland. The U.S. Food and Drug Administration inspected the plant in January 2026 and found violations involving two unrelated drugs. The agency sent Sanofi a warning letter on June 22, saying the company had not addressed an underlying failure to comply with manufacturing requirements. According to Sanofi, work to address the FDA’s continuing concerns contributed to the disruption in its Pompe treatments.

The company’s drugs Lumizyme and Nexviazyme replace an enzyme that people with Pompe disease lack. Patients typically receive infusions every two weeks. Orlando resident Monique Griffin, who has taken Lumizyme since 2010, said her next infusion was canceled after Sanofi notified her of a shipping delay. She fears a prolonged interruption could worsen her condition.

Some patients and families also criticized what they saw as insufficient warning. Sanofi said it had contacted patient organizations, patients and clinicians as the extent of the disruption became clearer and was continuing to provide updates. Spokesman Evan Berland said there were no drug-quality issues and that Sanofi was prioritizing the most vulnerable patients. He cautioned that the medicines are not interchangeable and advised patients to consult a health professional before changing treatments. The FDA said patient access was a priority and that it had offered Sanofi assistance.

Further reading